Company: NCEL
Filing Date: 2025-02-10
Form Type: F-3
Source: 0001213900-25-011823
Chunk: 28

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: F-3
Chunk 28
---
 exact physiological levels of insulin to maintain long-term continuous balanced glucose levels with minimal risk,
personal comfort and increased compliance for treatment.

<div align='center'>17</div>

Strengths Kadimastem’s vision is to utilize cell therapy treatments for incurable diseases that impair patients’ life expectancy and quality of life, such as Type 1 diabetes. The strategy is to replace the functionality of malfunctioning cells even within some distance from the original tissue/organ that is difficult or impossible to replace. The activity of malfunctioning insulin secreting cells can be restored using “healthy” islet cells that perform their physiological role upon their implantation. Kadimastem believes they have the potential to transform the lives of individuals living with Type 1 Diabetes and in the future Type 2 Diabetes which are insulin dependent. Kadimastem’s key competitive strengths include:

| ● | Kadimastem developed large scale manufacturing capabilities for IsletRx cells for clinical applications |

| ● | Kadimastem plans to utilize multiple delivery strategies, developed in-house or in collaboration |

| ● | Kadimastem has a unique, IP protected technology for “enrichment” of the therapeutically relevant pancreatic islet cells that results in increased safety and efficacy profile |

<div align='center'>18</div>

IsletRx - Development of a Drug for the Treatment of Diabetes

The IsletRx cells for diabetes
therapy Kadimastem develops is based on differentiation of pluripotent stem cells received under license agreements. Kadimastem developed
technologies for the cultivation of pluripotent stem cells and their differentiation into islet-like cell clusters (containing mainly
insulin-producing beta cells and to lesser extent glucagon-producing alpha cells). These cells are intended for transplantation into Type
1 diabetic patients whose beta cells are unable to produce insulin and release it in response to an increase in blood sugar, as well as
adequate levels of active glucagon that can respond to a sharp drop in glucose levels (hypoglycaemia). In this way, the transplant recipient
can produce, and release insulin or glucagon as needed, independently of external monitoring of blood sugar and regular insulin injection.
The drug Kadimastem is developing is intended for patients with Type 1 diabetes and in the future also for patients with Type 2 diabetes
who are dependent on injecting insulin from an external source to maintain adequate levels of sugar (glucose) in the blood.

Patients with uncontrolled
diabetes suffer from long-term complications such as vascular